Search tips
Search criteria 


Logo of plosonePLoS OneView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
PLoS One. 2013; 8(2): e57060.
Published online 2013 February 20. doi:  10.1371/journal.pone.0057060
PMCID: PMC3577762

Association between a Novel Mutation in SLC20A2 and Familial Idiopathic Basal Ganglia Calcification

Osman El-Maarri, Editor


Familial idiopathic basal ganglia calcification (FIBGC) is a rare, autosomal dominant disorder involving bilateral calcification of the basal ganglia. To identify gene mutations related to a Chinese FIBGC lineage, we evaluated available individuals in the family using CT scans. DNA was extracted from the peripheral blood of available family members, and both exonic and flanking intronic sequences of the SLC20A2 gene were amplified by PCR and then sequenced. Non-denaturing polyacrylamide gel electrophoresis (PAGE) was used to confirm the presence of mutations. Allele imbalances of the SLC20A2 gene or relative quantity of SLC20A2 transcripts were evaluated using qRT-PCR. A novel heterozygous single base-pair deletion (c.510delA) within the SLC20A2 gene was identified. This deletion mutation was found to co-segregate with basal ganglia calcification in all of the affected family members but was not detected in unaffected individuals or in 167 unrelated Han Chinese controls. The mutation will cause a frameshift, producing a truncated SLC20A2 protein with a premature termination codon, most likely leading to the complete loss of function of the SLC20A2 protein. This mutation may also lead to a reduction in SLC20A2 mRNA expression by approximately 30% in cells from affected individuals. In conclusion, we identified a novel mutation in SLC20A2 that is linked to FIBGC. In addition to the loss of function at the protein level, decreasing the expression of SLC20A2 mRNA may be another mechanism that can regulate SLC20A2 function in IBGC individuals. We propose that the regional expression pattern of SLC20A1 and SLC20A2 might explain the unique calcification pattern observed in FIBGC patients.


Calcification of basal ganglia is not uncommon. In clinical settings, this situation can be found secondary to various pathologic processes including hypoparathyroidism, infections, brain tumors, and radiation damage [1]. However, the calcification of basal ganglia may also occur as an idiopathic condition. This is known as familial idiopathic basal ganglia calcification (FIBGC) or Fahr disease [2]. Although rare, FIBGC has attracted the interest of neuroscientists ever since Fahr first described it in 1930 [3]. This unique clinical entity has often been associated with neurobehavioral and cognitive changes [1], [2]. The identification of its genetic background may provide an explanation for the formation of abnormal intracerebral calcifications and provide insight into the different pathways that lead to dysfunction of the basal ganglia.

FIBGC is often presented as a disorder with autosomal dominant inheritance. Its pathogenetic basis has been linked to chromosomes such as 14q13, 2q37, and 8q21.1-q11.23 [4][6]. Recently, Wang et al. sequenced the 8q21.1-q11.23 locus and confirmed that loss of function of SLC20A2, which is a type III sodium-dependent phosphate transporter, is the molecular basis for a large subset of IBGC [7]. They suggested that disturbed regional Pi homeostasis is the primary pathophysiologic mechanism of IBGC. However, familial IBGC has been reported to be genetically heterogeneous [8]. Further investigation of other genetic mutations may be necessary for fully understanding its molecular background.


Study subjects and MRS evaluation

A Chinese family affected by FIBGC with an autosomal dominant pattern of inheritance is depicted in Fig. 1A. The 4-year-old girl received a CT scan because her mother had found her convulsing after crying. At the mother's request, we performed the CT scans on her other daughter as well. There were 5 affected individuals in the 3 generations (Fig. 1A). In this study, the term “affected individuals” refers to both symptomatic and asymptomatic family members with calcification on brain CT scans, except II:3, whose CT image was not available, but genetic analysis confirmed the existence of FIBGC related SLC20A2 mutation, as in other affected members of this family (Fig. 1B). Written informed consent was obtained according to the Declaration of Helsinki, and the ethical committee of China Medical University approved this study.

Figure 1
Study subjects and imaging evaluation.

The 4-year-old girl, who had minimal calcification of the basal ganglia area, also received a magnetic resonance spectroscopy (MRS) evaluation. Images were obtained using an 8-channel brain-phased array coil and a 3.0-T imaging system (Signa; GE Medical Systems, Milwaukee, WI, U.S.A.). Single-voxel spectroscopy was performed with PRESS technique (echo time 144 ms, repetition time 1500 ms); 2 cm-sided voxels were located in the basal ganglia and left frontal cortex. The basal ganglia voxels centered on the internal part of the globus pallidus, which showed minimal calcification. Peaks of cerebral metabolites were identified according to their chemical shifts. With a TE of 144 ms, lactate was defined as inverted peaks (doublet at 1.28 and 1.38 ppm), and lipid levels were found to be suppressed.

Analysis of SLC20A2 mutation

Peripheral blood samples were collected from the available members of the Chinese family with IBGC after informed consent was provided by each. Genomic DNA was extracted using a universal genomic DNA extraction kit (TaKaRa, Japan). All 11 exons and the flanking intronic sequences of the SLC20A2 gene (Genbank accession number: NG_032161) were amplified using polymerase chain reaction (PCR). PCR-amplified DNA fragments were gel-purified and then subjected to DNA sequencing using both forward and reverse primers with the ABI BigDye Terminator Cycle Sequencing Kit v3.1 on an ABI PRISM 3730XL Genetic Analyzer (Applied Biosystems, Inc, Foster City, California, USA). Information about the primer sequences is given in Table 1. The new sequence data has been deposited in GenBank under the accession number KC176705.

Table 1
Sequences and positions of the primers used for mutation analysis of SLC20A2.

Non-denaturing polyacrylamide gel electrophoresis (PAGE)

To confirm the presence of the c.510delA mutation, the PCR amplicons generated with primers delF (5′- GTTTATATCTCCACTGTTGTCTGG -3′) and delR (5′- ACAATTATTCCTCTAACCCCTCTC -3′) were denatured at 95°C for 5 min and annealed by cooling to 25°C (5°C/min) in the thermal cycler. The resultant heteroduplexes and homoduplexes were mixed with 6× gel loading buffer, subjected to electrophoresis in an 8% non-denaturing polyacrylamide gel (30[ratio]0.8 Acrylamide[ratio]Bis), which had been pre-run at 200 V for 30 min. Then, electrophoresis of the samples was performed at 400 V for 4 h. TBE buffer (1×) was pumped to cycle between the upper and lower electrophoresis buffer tanks. DNAs were silver-stained and analyzed visually [9]. All family members and 167 unrelated normal controls were included in the non-denaturing PAGE analysis.

Analysis of mRNA expression

Total RNA was isolated using the Trizol reagent from the peripheral blood of the family members according to the manufacturer's instructions (Invitrogen, Carlsbad, CA, U.S.A.). Reverse transcription (RT) was performed using a PrimeScript® RT Reagent Kit with gDNA Eraser (Takara, Japan) in a 20 µl reaction mixture containing 1 µg of total RNA from each individual sample. To assess the expression of the mutant SLC20A2 alleles, RT-PCR was carried out with primers RT-F (5′-AGGTGCCAAGGCTAATGATGAC-3′) and RT-R (5′-GGACAGTGCTCTTCCGTATGC-3′) using RNA from the family members and normal controls. The cDNA fragments produced were then sequenced using the same primers. Quantitative real-time RT-PCR (qRT-PCR) was used to quantify the relative mRNA expression of SLC20A2 in affected individuals and normal controls. The qRT-PCR primers are given in Table 1. The amplicon of SLC20A2 that was generated was 124 bp in length, and was normalized to a 114 bp glyceraldehyde-3-phosphate dehydrogenase (GAPDH) fragment. The relative expression level was determined on the basis of the comparative ΔΔCT method using the reverse transcription products from peripheral blood samples from a normal individual as calibrators [10]. qRT-PCR was carried out in a total volume of 25 µl, with each tube containing 12.5 µl of SYBR Premix Ex Taq (Takara), 4 µl of reverse transcription product (40 ng) and 2 µl of primers (400 nM each). Three replicates were conducted per sample. Reactions were run in a Rotor-Gene 3000 real-time rotary analyzer (Corbett Life Science) at 95°C for 3 min and then 45 cycles at 95°C for 5 s and 60°C for 20 s. The qRT-PCR experiments were repeated three or four times.


Clinical findings in family PJ-IBGC

In this study, we evaluated the available members of the small Chinese IBGC lineage using CT and serum examination, except II:3. The affected individuals showed symmetrical bilateral basal ganglia calcification (Fig. 1B). In this lineage, only one 54-year-old man showed minimal symptoms, specifically changes in mood and declining memory, while everyone else showed no sign of pyramidal or extrapyramidal symptoms. All of the serum examinations were normal for all available individuals in this lineage. No abnormal lactate peak was observed at the basal ganglia (calcified area) or frontal cortex (uncalcified area) in the 4-year-old FIBGC patient (Fig. 1C).

Identification of a novel SLC20A2 mutation

Upon screening for SLC20A2 mutations in the PJ-IBGC family, we identified a heterozygous single base-pair deletion, c.510delA (p.R172fsX19), in SLC20A2 exon 4 (Fig. 2A). We confirmed the mutation in all affected individuals of the family through DNA sequencing, but did not detect the mutation in any unaffected family members. We then carried out the heteroduplex assay in all family members and 167 unrelated normal individuals. By denaturing and reannealing the PCR products, two types of bands were observed after PAGE. The band at the bottom occurred due to a perfect match of the nucleotide sequences (homoduplex). The upper bands were specific heteroduplex bands, which had a single-nucleotide deletion gap in one relative to a second sequence, and showed reduced mobility in PAGE. Amplicons of all of the affected individuals showed two fragments on non-denaturing PAGE, but only a single homoduplex band was observed in amplicons of all the unaffected and normal controls (Fig. 2B). This indicated that the patients were heterozygous for the specific mutation detected. With this heteroduplex assay, we confirmed that the deletion mutation co-segregated with basal ganglia calcification in all affected family members, but it was not detected in unaffected individuals or in the 167 unrelated controls. The c.510delA mutation, also called p.R172fsX19 at the protein level, results in a frameshift, producing a truncated SLC20A2 protein with a PTC (premature termination codon) (Fig. 2C). Bøttger et al. have shown that the fragment of L183-V483 of human SLC20A2 is critical for Pi transport function [11]. Thus the c.510delA frameshift mutation is likely to lead to a complete loss-of-function of the SLC20A2 protein.

Figure 2
Identification of the c.510delA SLC20A2 mutation.

Detection of allele imbalance from the wild-type and mutant SLC20A2

To assess SLC20A2 expression at the mRNA level, RT-PCR fragments spanning the heterozygous mutation were sequenced simultaneously with PCR products derived from genomic DNA of the same affected individuals. In RT-PCR assays, cDNA fragments of the expected size were observed both in normal and affected individuals. No additional bands were detected in the affected individuals, excluding the possibility of exon skipping due to the c.510delA mutation within exon 4 (data not shown). In sequencing, a marked allele imbalance was observed in cDNA from all affected individuals, suggesting lower mRNA expression of the mutant SLC20A2 allele (Fig. 3A). This imbalance was not detectable in unaffected family members or in unrelated normal controls, which suggested the presence of a difference in copy number between affected and unaffected family members.

Figure 3
mRNA expression analysis of the SLC20A2 mutation.

Relative quantity of SLC20A2 transcripts

To find out whether SLC20A2 is associated with copy number mutations in the PJ-IBGC family, qRT-PCR was used to determine the relative copy number (RCN) of the SLC20A2 based on the ΔΔCT method. We examined the 3 affected individuals and an unrelated normal control, and the RCNs were 0.66 (mean ± SD 0.66±0.081), 0.67 (mean ± SD 0.67±0.047), 0.68 (mean ± SD 0.68±0.092) and 0.97 (mean ± SD 0.97±0.032) (Fig. 3B). These data indicate that the SLC20A2 mRNA expression in peripheral blood samples from normal individuals were constant, but that there was an approximately 30% reduction in cells from affected individuals.


Familial IBGC, also known as Fahr disease, is a rare disorder. Its major clinical features include symmetrical bilateral calcification of the basal ganglia in the absence of any abnormal serum levels of calcium or phosphorus [1]. The patients may show different symptoms, including cognitive impairment, schizophrenia, parkinsonism, and cerebellar ataxia, ranging in severity from undetectable to severe [1], [2].

Dai et al. mapped an IBGC locus to chromosome 8p21.1-q11.23 in a study performed on a large Chinese family [6]. Recently, Dai's research group sequenced candidate genes in this locus and identified several mutations in SLC20A2 [7]. 32Pi transport assays in Xenopus laevis oocytes showed that the mutations resulted in significant impairment of Pi transport. In the present study, we screened for the SLC20A2 mutations in the PJ-IBGC family, and identified a novel heterozygous single base-pair deletion, c.510delA (p.R172fsX19), in SLC20A2 exon 4. The mutation is predicted to result in a frameshift, producing a truncated SLC protein with a premature termination codon, which most likely leads to a complete loss of function in SLC20A2. Compared with the work of Wang et al. [7], we performed further confirmation by directly examining the SLC20A2 mRNA expression in cells from affected individuals and showed a 30% reduction. Our research indicates that insufficient expression of SLC20A2 is the molecular basis for FIBGC.

Pi is indispensable for all life processes, and Pi homeostasis is precisely controlled at several levels by sodium/phosphate co-transporters. Type-2 sodium/phosphate co-transporters (SLC34) are strongly expressed in the kidneys and intestinal mucosa; they are involved in the absorption of Pi from the intestine and the recycling of Pi from the kidneys [12]. SLC20A2, also known as pit2, is a type III Na-Pi co-transporter. The type III Na-Pi co-transporters are expressed in all investigated tissues and cells of the human body [13]. Both SLC20A1 and SLC20A2 have been used by viruses as receptors for cell invasion [14], [15]. The widespread expression of SLC20A1 and SLC20A2 indicates that they may play a key role in the regulation of Pi homeostasis at the micro-environmental level, and regional differential expression of these two proteins may lead to a different local level of Pi. This may affect Pi-related physical processes, including calcification.

Although a mutation in SLC20A2 was identified as the genetic basis for the IBGC, several questions still need to be answered: 1. If all of the cells within the body have the same mutation, why does the calcification only occur within the brain? 2. Why does the calcification usually begin in the globus pallidus? 3. Is the location of the calcification consistent with expression of SLC20A2? The expression of SLC20A2 within mouse and human brains was investigated (Allen Brain Atlas, The results show that the expression of SLC20A2 was high in regions that usually show calcification in IBGC patients, such as the basal ganglia, cerebral cortex, and cerebellar cortex. However, in some regions, such as the substantia nigra (SN), SLC20A2 was also expressed at high levels, but IBGC patients never show a calcification in this area. For this reason, other factors may also be involved in the calcification process. Villa-Bellosta et al. showed that SLC20A2 function could be regulated by acidosis [16]. We performed MRS to determine the local lactate level. Lactate is a marker of metabolic activity, and abnormal accumulation of lactate may indicate regional acidosis. The 4-year-old girl with minimal calcification was evaluated with MRS, and we did not find any increase in lactate level in the calcified areas or any difference in lactate level between the calcified area and the unaffected area. In addition, other studies have shown no significant regional variations in pH value within the human brain [17]. As a result, acidosis does not seem to be involved in the regulation of Pi homeostasis in the brain.

Pathological analysis of IBGC individuals showed that the calcification of IBGC involved the media and intima of cerebral vessels, including small arteries, small veins and capillaries [18]. This is consistent with the minimal and late onset of the symptoms because no neuronal damage occurs during the early stages of IBGC. Studies on the pathogenesis of vascular calcification induced by phosphate showed that SLC20A1 has a determinant role in the mineralization of vascular cells in vitro [19], [20]. For this reason, we propose that both SLC20A1 and SLC20A2 might be involved in the pathogenesis of FIBGC. It has been previously demonstrated that both SLC20A1 and SLC20A2 are expressed in the brain but in different patterns [21]. The basal ganglia area expresses high levels of SLC20A2 but low levels of SLC20A1, which may make this area vulnerable to SLC20A2 mutation. Researchers have also found that SLC20A2 expression cannot be regulated in the brain, which makes SLC20A2 an ideal target gene for IBGC [21]. Although the SN has an expression pattern similar to that shown by SLC20A1 and SLC20A2 in the basal ganglia, SLC20A1 expression can be up-regulated in this area [21]. This may compensate for the mutation of SLC20A2 and maintain the local Pi homeostasis. We speculate that, although SLC20A2 is widely expressed outside brain, the co-expressed SLC20A1 may compensate for mutations in SLC20A2 and render the cells outside of the brain resistant to SLC20A2 mutations. This may be an explanation for why no calcification takes place outside the brain in IBGC patients. The unique expression of both SLC20A1 and SLC20A2 may explain the specific calcification pattern observed in IBGC.

In conclusion, we identified a novel SLC20A2 mutation, which causes a significant decrease in SLC20A2 mRNA expression. Our results indicate that the insufficient SLC20A2 expression caused by the SLC20A2 mutation is the molecular basis for the pathogenesis of IBGC and that insufficient SLC20A2 expression may lead to abnormal local Pi homeostasis and then to calcification of the basal ganglia. To explain the unique calcification pattern of IBGC patients, we here propose a hypothesis that the regional expression pattern of SLC20A1and SLC20A2 may be the molecular basis for IBGC. Our hypothesis has partial support from our results and the literature reviews. However, this hypothesis requires further careful investigation.


We would like to thank all of the family members who participated in this study.

Funding Statement

This work was mainly supported by the National Natural Science Foundation of China (81071283). The funder's website: The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding was received for this study


1. Casanova MF, Araque JM (2003) Mineralization of the basal ganglia: implications for neuropsychiatry, pathology and neuroimaging. Psychiatry research 121: 59–87 [PubMed]
2. Manyam BV, Walters AS, Narla KR (2001) Bilateral striopallidodentate calcinosis: clinical characteristics of patients seen in a registry. Movement disorders : official journal of the Movement Disorder Society 16: 258–264 [PubMed]
3. Manyam BV (2005) What is and what is not ‘Fahr's disease’. Parkinsonism & related disorders 112:73–80 [PubMed]
4. Geschwind DH, Loginov M, Stern JM (1999) Identification of a locus on chromosome 14q for idiopathic basal ganglia calcification (Fahr disease). American journal of human genetics 65: 764–772 [PubMed]
5. Volpato CB, De Grandi A, Buffone E, Facheris M, Gebert U, et al. (2009) 2q37 as a susceptibility locus for idiopathic basal ganglia calcification (IBGC) in a large South Tyrolean family. Journal of molecular neuroscience : MN 39: 346–353 [PubMed]
6. Dai X, Gao Y, Xu Z, Cui X, Liu J, et al. (2010) Identification of a novel genetic locus on chromosome 8p21.1-q11.23 for idiopathic basal ganglia calcification. American journal of medical genetics Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics 153B: 1305–1310 [PubMed]
7. Wang C, Li Y, Shi L, Ren J, Patti M, et al. (2012) Mutations in SLC20A2 link familial idiopathic basal ganglia calcification with phosphate homeostasis. Nature genetics 44: 254–256 [PubMed]
8. Oliveira JR, Spiteri E, Sobrido MJ, Hopfer S, Klepper J, et al. (2004) Genetic heterogeneity in familial idiopathic basal ganglia calcification (Fahr disease). Neurology 63: 2165–2167 [PubMed]
9. Waléria-Aleixo A, Kroon EG, Campos MA, Margutti-Pinto ME, Bonjardim CA, et al. (2000) Heteroduplex mobility assay for rapid, sensitive and specific detection of mycobacteria. Diagnostic microbiology and infectious disease 36: 225–235 [PubMed]
10. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods 25: 402–408 [PubMed]
11. Bøttger P, Pedersen L (2011) Mapping of the minimal inorganic phosphate transporting unit of human PiT2 suggests a structure universal to PiT-related proteins from all kingdoms of life. BMC Biochemistry 12: 21. [PMC free article] [PubMed]
12. Werner A, Dehmelt L, Nalbant P (1998) Na+-dependent phosphate cotransporters: the NaPi protein families. The Journal of experimental biology 201: 3135–3142 [PubMed]
13. Uckert W, Willimsky G, Pedersen FS, Blankenstein T, Pedersen L (1998) RNA levels of human retrovirus receptors Pit1 and Pit2 do not correlate with infectibility by three retroviral vector pseudotypes. Human gene therapy 9: 2619–2627 [PubMed]
14. O'Hara B, Johann SV, Klinger HP, Blair DG, Rubinson H, et al. (1990) Characterization of a human gene conferring sensitivity to infection by gibbon ape leukemia virus. Cell growth & differentiation 1: 119–127 [PubMed]
15. Van Zeijl M, Johann SV, Closs E, Cunningham J, Eddy R, et al. (1994) A human amphotropic retrovirus receptor is a second member of the gibbon ape leukemia virus receptor family. Proceeding of the national academy of sciences of the united states of america 91: 1168–1172 [PubMed]
16. Villa-Bellosta R, Sorribas V (2010) Compensatory regulation of the sodium/phosphate cotransporters NaPi-IIc (SCL34A3) and Pit-2 (SLC20A2) during Pi deprivation and acidosis. Pflugers Archiv : European journal of physiology 459: 499–508 [PubMed]
17. Barker PB, Butterworth EJ, Boska MD, Nelson J, Welch KM (1999) Magnesium and pH imaging of the human brain at 3.0 Tesla. Magnetic resonance in medicine : official journal of the Society of Magnetic Resonance in Medicine/Society of Magnetic Resonance in Medicine 41: 400–406 [PubMed]
18. Tsuchiya Y, Ubara Y, Anzai M, Hiramatsu R, Suwabe T, et al. (2011) A case of idiopathic basal ganglia calcification associated with membranoproliferative glomerulonephritis. Internal medicine 50: 2351–2356 [PubMed]
19. Gonzalez M, Martinez R, Amador C, Michea L (2009) Regulation of the sodium-phosphate cotransporter Pit-1 and its role in vascular calcification. Current vascular pharmacology 7: 506–512 [PubMed]
20. Li X, Yang HY, Giachelli CM (2006) Role of the sodium-dependent phosphate cotransporter, Pit-1, in vascular smooth muscle cell calcification. Circulation research 98: 905–912 [PubMed]
21. Lagrue E, Abe H, Lavanya M, Touhami J, Bodard S, et al. (2010) Regional characterization of energy metabolism in the brain of normal and MPTP-intoxicated mice using new markers of glucose and phosphate transport. Journal of biomedical science 17: 91. [PMC free article] [PubMed]

Articles from PLoS ONE are provided here courtesy of Public Library of Science